One year experience with erenumab: real-life data in 30 consecutive patients
暂无分享，去创建一个
Mariana Rippa | K. Longo | V. Manzo | R. Renna | M. Napolitano | G. Maniscalco | C. Florio | A. Sagnelli | A. Ranieri | Walter Di Iorio | G. Servillo | P. Candelaresi | Simona Salvatore | G. Alfieri
[1] A. Tessitore,et al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience , 2020, The Journal of Headache and Pain.
[2] S. Sacco,et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy , 2020, The Journal of Headache and Pain.
[3] Gaigai Li,et al. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis , 2019, BMC Neurology.